Ferrari N.V.HARES (NYSE:RACE) had a decrease of 4.29% in short interest. RACE’s SI was 2.44 million shares in July as released by FINRA. Its down 4.29% from 2.55 million shares previously. With 461,300 avg volume, 5 days are for Ferrari N.V.HARES (NYSE:RACE)’s short sellers to cover RACE’s short positions. The SI to Ferrari N.V.HARES’s float is 1.45%. The stock decreased 1.30% or $2.2 during the last trading session, reaching $166.5. About 334,038 shares traded. Ferrari N.V. (NYSE:RACE) has risen 6.24% since July 20, 2018 and is uptrending. It has outperformed by 1.81% the SP500. Some Historical RACE News: 18/05/2018 – FERRARI SAYS APPOINTS ANTONIO PICCA PICCON AS CFO; 28/04/2018 – SEBASTIAN VETTEL TAKES POLE POSITION FOR FERRARI AT AZERBAIJAN FORMULA ONE GRAND PRIX; 03/05/2018 – Motor racing-Ferrari’s Marchionne ‘encouraged’ by F1 engine proposals; 12/03/2018 – Huntsman Appoints Daniele Ferrari to Its Bd of Directors; 03/05/2018 – FERRARI PORTOFINO SOLD OUT FOR 2018: MARCHIONNE; 04/04/2018 – Motor racing-Formula One teams, minus Ferrari, commit to esports series; 06/03/2018 – MARCHIONNE: FERRARI IN TALKS TO FINALIZE PATENT BOX BENEFIT; 18/05/2018 – Ferrari: Alessandro Gili to Leave Company Effective May 31; 18/05/2018 – Ferrari Appoints Antonio Picca Piccon as new CFO; 25/04/2018 – Books: `In Italy, There Was the Pope and Then There Was Enzo Ferrari’
Analysts expect ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) to report $-0.20 EPS on August, 5.They anticipate $0.15 EPS change or 42.86% from last quarter’s $-0.35 EPS. After having $-0.15 EPS previously, ASLAN Pharmaceuticals Limited’s analysts see 33.33% EPS growth. The stock increased 2.22% or $0.07 during the last trading session, reaching $3.22. About 5,043 shares traded. ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) has declined 44.76% since July 20, 2018 and is downtrending. It has underperformed by 49.19% the SP500. Some Historical ASLN News: 17/05/2018 ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO
Among 4 analysts covering Ferrari (NYSE:RACE), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ferrari had 7 analyst reports since May 1, 2019 according to SRatingsIntel. The stock of Ferrari N.V. (NYSE:RACE) earned “Buy” rating by Bank of America on Thursday, July 18. The stock has “Outperform” rating by Credit Suisse on Thursday, June 20. The firm has “Overweight” rating given on Thursday, May 9 by Morgan Stanley. The rating was maintained by UBS on Wednesday, July 3 with “Buy”.
More notable recent Ferrari N.V. (NYSE:RACE) news were published by: Streetinsider.com which released: “Goldman Sachs Transfers Coverage on Ferrari NV (RACE:IM) (RACE) at Neutral – StreetInsider.com” on July 16, 2019, also Livetradingnews.com with their article: “Ferrari’s (NYSE:RACE) New SF90 Stradale HyperSuper Car, How it Works – Live Trading News” published on July 19, 2019, Seekingalpha.com published: “Ferrari: Beyond Fully Valued – Seeking Alpha” on July 10, 2019. More interesting news about Ferrari N.V. (NYSE:RACE) were released by: Livetradingnews.com and their article: “Ferrari (NYSE:RACE) 1 Year After Marchionneâ€™s Passing, Stronger Than Ever – Live Trading News” published on July 18, 2019 as well as Livetradingnews.com‘s news article titled: “Ferrari (NYSE:RACE) Readying 812sf Spider to Debut in September – Live Trading News” with publication date: July 18, 2019.
Ferrari N.V., through with its subsidiaries, designs, engineers, produces, and sells luxury performance sports cars. The company has market cap of $40.51 billion. The firm offers seven models, including four sports cars that include 488 GTB, 488 Spider, F12berlinetta, and special series F12tfd; and three GT cars, which comprise California T, GTC4Lusso, and GTC4Lusso T. It has a 37.12 P/E ratio. It also provides LaFerrari Aperta, a limited edition supercar; Fuoriserie, a very limited editions series; one-off cars; F60 America, a V12 open air roadster; and Ferrari J50, a two-seater mid-rear-engined roadster.
More notable recent ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) news were published by: Finance.Yahoo.com which released: “The Week Ahead In Biotech: Pending Clinical Readouts In Focus – Yahoo Finance” on June 29, 2019, also Nasdaq.com with their article: “ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Strong Buy: Here’s Why – Nasdaq” published on July 01, 2019, Finance.Yahoo.com published: “ASLAN Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update – Yahoo Finance” on April 29, 2019. More interesting news about ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) were released by: Seekingalpha.com and their article: “Aslan Pharmaceuticals: An Asia-Focused Oncology Company – Seeking Alpha” published on April 04, 2019 as well as Seekingalpha.com‘s news article titled: “ASLAN Pharmaceuticals completes enrollment in TreeTopp study – Seeking Alpha” with publication date: January 02, 2019.
ASLAN Pharmaceuticals Limited operates as a clinical-stage oncology and inflammatory disease focused biopharmaceutical firm in the United States. The company has market cap of $106.98 million. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. It currently has negative earnings. The company’s lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor , inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4, as well as gastric cancer.